Search

Your search keyword '"Bois FY"' showing total 135 results

Search Constraints

Start Over You searched for: Author "Bois FY" Remove constraint Author: "Bois FY"
135 results on '"Bois FY"'

Search Results

1. Population toxicokinetics of benzene.

2. Evaluating health risks from occupational exposure to pesticides and the regulatory response.

3. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results.

4. Estimating metabolic rate for butadiene at steady state using a Bayesian physiologically-based pharmacokinetic model

5. A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism

8. Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation.

9. Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework.

10. A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator.

11. A Bayesian framework for virtual comparative trials and bioequivalence assessments.

12. Mapping Interindividual Variability of Toxicodynamics Using High-Throughput Transcriptomics and Primary Human Hepatocytes from Fifty Donors.

13. Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn's Disease Patients through PBPK Modeling.

14. SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp ® simulator.

15. Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic Framework.

16. A quantitative AOP of mitochondrial toxicity based on data from three cell lines.

17. Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.

18. PBPK Modeling to Simulate the Fate of Compounds in Living Organisms.

19. Application of evidence-based methods to construct mechanism-driven chemical assessment frameworks.

20. A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms.

21. Opening a debate on open-source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate.

22. Multistate models of developmental toxicity: Application to valproic acid-induced malformations in the zebrafish embryo.

24. Well-tempered MCMC simulations for population pharmacokinetic models.

25. A generic PBTK model implemented in the MCRA platform: Predictive performance and uses in risk assessment of chemicals.

26. Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models.

27. Development of a generic zebrafish embryo PBPK model and application to the developmental toxicity assessment of valproic acid analogs.

28. Prediction of maternal and foetal exposures to perfluoroalkyl compounds in a Spanish birth cohort using toxicokinetic modelling.

29. Advancing human health risk assessment.

31. Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim.

32. Generic physiologically-based toxicokinetic modelling for fish: Integration of environmental factors and species variability.

33. Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases.

34. Analysis of Time-Series Gene Expression Data to Explore Mechanisms of Chemical-Induced Hepatic Steatosis Toxicity.

35. Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling.

36. Multiscale modelling approaches for assessing cosmetic ingredients safety.

37. Adverse outcome pathways: opportunities, limitations and open questions.

38. Ab initio chemical safety assessment: A workflow based on exposure considerations and non-animal methods.

39. High-Throughput Analysis of Ovarian Cycle Disruption by Mixtures of Aromatase Inhibitors.

40. Toxicokinetic models and related tools in environmental risk assessment of chemicals.

41. The Next Generation of Risk Assessment Multi-Year Study-Highlights of Findings, Applications to Risk Assessment, and Future Directions.

42. Identifiability of sorption parameters in stirred flow-through reactor experiments and their identification with a Bayesian approach.

43. Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.

44. Modeling Pharmacokinetics.

45. Quantitative in vitro to in vivo extrapolation of tissues toxicity.

46. Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems.

48. Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group.

49. Integrated Testing Strategies (ITS) for safety assessment.

50. Probabilistic generation of random networks taking into account information on motifs occurrence.

Catalog

Books, media, physical & digital resources